CONTENTS

14 FORECAST: CHRONIC HEART FAILURE (Published on 11 December 2017)
14 OVERVIEW
15 EXECUTIVE SUMMARY
16 MARKET DYNAMICS
23 FORECAST AND FUTURE TRENDS
51 MARKET DEFINITION AND METHODOLOGY
58 PRIMARY RESEARCH METHODOLOGY
60 BIBLIOGRAPHY
63 PRODUCT PROFILE (LATE STAGE): C-CURE
73 PRODUCT PROFILE: CORLANOR
85 PRODUCT PROFILE: ENTRESTO
100 PRODUCT PROFILE (LATE STAGE): FARXIGA
109 PRODUCT PROFILE (LATE STAGE): JARDIANCE
119 PRODUCT PROFILE (LATE STAGE): MPC-150-IM
130 PRODUCT PROFILE (LATE STAGE): XARELTO
140 PRODUCT PROFILE (LATE STAGE): OMECAMTIV MECARBIL
150 PRODUCT PROFILE (LATE STAGE): VERICIGUAT

160 TREATMENT: CHRONIC HEART FAILURE (Published on 04 October 2017)
160 OVERVIEW
161 EXECUTIVE SUMMARY
162 PRIMARY RESEARCH METHODOLOGY
164 DISEASE DEFINITION AND DIAGNOSIS
171 PATIENT SEGMENTATION
178 CURRENT TREATMENT OPTIONS
181 PRESCRIBING TRENDS: CHF WITH REDUCED EJECTION FRACTION
199 PRESCRIBING TRENDS: CHF WITH PRESERVED EJECTION FRACTION
213 COMPLIANCE RATES

214 EPIDEMIOLOGY: CHRONIC HEART FAILURE (Published on 03 January 2019)
214 OVERVIEW
215 DISEASE BACKGROUND
217 METHODOLOGY
224 FORECAST
229 BIBLIOGRAPHY
231 APPENDIX: ADDITIONAL SOURCES

233 MARKETED DRUGS: CHRONIC HEART FAILURE (Published on 11 December 2017)
233 OVERVIEW
234 EXECUTIVE SUMMARY
235 PRODUCT OVERVIEW
237 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
241 ANGIOTENSIN RECEPTOR BLOCKERS
243 BETA BLOCKERS
246 ALDOSTERONE ANTAGONISTS
248 OTHER DRUG CLASSES
250 PRODUCT PROFILE: CORLANOR
262 PRODUCT PROFILE: ENTRESTO

277 CHRONIC HEART FAILURE PRICING, REIMBURSEMENT, AND ACCESS (Published on 13 April 2018)
277 OVERVIEW
278 EXECUTIVE SUMMARY
279 REGULATORY LABELS AND GUIDELINES
282 GLOBAL ACCESS LEVERS
290 EVIDENCE AND VALUE
301 ACCESS TO RECENTLY APPROVED AND PIPELINE PRODUCTS
305 PRICING
306 US
314 CANADA
318 FRANCE
325 GERMANY
330 ITALY
333 SPAIN
336 UK
344 METHODOLOGY

347 PIPELINE: CHRONIC HEART FAILURE (Published on 11 December 2017)
347 OVERVIEW
348 EXECUTIVE SUMMARY
349 CLINICAL PIPELINE OVERVIEW
350 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
351 PRODUCT PROFILE (LATE STAGE): C-CURE
361 PRODUCT PROFILE (LATE STAGE): FARXIGA
370 PRODUCT PROFILE (LATE STAGE): JARDIANCE
380 PRODUCT PROFILE (LATE STAGE): MPC-150-IM
391 PRODUCT PROFILE (LATE STAGE): XARELTO
401 PRODUCT PROFILE (LATE STAGE): OMECAMTIV MECARBIL
411 PRODUCT PROFILE (LATE STAGE): VERICIGUAT

LIST OF FIGURES
16 Figure 1: Chronic heart failure – current and future market dynamics analysis
17 Figure 2: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for chronic heart failure
24 Figure 3: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country, 2017–26
26 Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
29 Figure 5: Sales of Jardiance and Farxiga in the US, Japan, and five major EU markets, 2017–26
31 Figure 6: Sales of generic ACE inhibitors and ARBs in the US, Japan, and five major EU markets, 2017–26
36 Figure 7: Sales of MPC-150-IM and C-Cure in the US, Japan, and five major EU markets, 2017–26
40 Figure 8: Sales of vericiguat and omecamtiv mecarbil in the US, Japan, and five major EU markets, 2017–26
44 Figure 9: Sales of Xarelto and rivaroxaban generics in the US, Japan, and five major EU markets, 2017–26
46 Figure 10: Chronic heart failure drug sales in the US, by class, 2017–26
47 Figure 11: Chronic heart failure drug sales in the five major EU markets, by country, 2017–26
48 Figure 12: Chronic heart failure drug sales in the five major EU markets, by class, 2017–26
50 Figure 13: Chronic heart failure drug sales in Japan, by class, 2017–26
54 Figure 14: Methodology flow for Datamonitor Healthcare’s chronic heart failure forecast
56 Figure 15: Price sources and calculations, by country
66 Figure 16: C-Cure for chronic heart failure – SWOT analysis
67 Figure 17: Datamonitor Healthcare’s drug assessment summary of C-Cure for chronic heart failure
68 Figure 18: Datamonitor Healthcare’s drug assessment summary of C-Cure for chronic heart failure
70 Figure 19: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
78 Figure 20: Corlanor for chronic heart failure – SWOT analysis
79 Figure 21: Datamonitor Healthcare’s drug assessment summary of Corlanor for chronic heart failure
80 Figure 22: Datamonitor Healthcare’s drug assessment summary of Corlanor for chronic heart failure
82 Figure 23: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
89 Figure 24: Entresto for chronic heart failure – SWOT analysis
90 Figure 25: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
91 Figure 26: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
96 Figure 27: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
102 Figure 28: Farxiga for chronic heart failure – SWOT analysis
103 Figure 29: Datamonitor Healthcare’s drug assessment summary of Farxiga for chronic heart failure
104 Figure 30: Datamonitor Healthcare’s drug assessment summary of Farxiga for chronic heart failure
106 Figure 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
112 Figure 32: Jardiance for chronic heart failure – SWOT analysis
113 Figure 33: Datamonitor Healthcare’s drug assessment summary of Jardiance for chronic heart failure
114 Figure 34: Datamonitor Healthcare’s drug assessment summary of Jardiance for chronic heart failure
116 Figure 35: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
122 Figure 36: MPC-150-IM for chronic heart failure – SWOT analysis
123 Figure 37: Datamonitor Healthcare’s drug assessment summary of MPC-150-IM for chronic heart failure
124 Figure 38: Datamonitor Healthcare’s drug assessment summary of MPC-150-IM for chronic heart failure
126 Figure 39: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
133 Figure 40: Xarelto for chronic heart failure – SWOT analysis
134 Figure 41: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
135 Figure 42: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
137 Figure 43: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
143 Figure 44: Omecamtiv mecarbil for chronic heart failure – SWOT analysis
144 Figure 45: Datamonitor Healthcare’s drug assessment summary of omecamtiv mecarbil for chronic heart failure
145 Figure 46: Datamonitor Healthcare’s drug assessment summary of omecamtiv mecarbil for chronic heart failure
147 Figure 47: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
153 Figure 48: Vericiguat for chronic heart failure – SWOT analysis
154 Figure 49: Datamonitor Healthcare’s drug assessment summary of vericiguat for chronic heart failure
155 Figure 50: Datamonitor Healthcare’s drug assessment summary of vericiguat for chronic heart failure
157 Figure 51: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
167 Figure 52: Diagnostic flow chart for patients with suspected heart failure
168 Figure 53: Percentage incidence of co-morbidities among chronic heart failure patients in the US, Japan, and five major EU markets, by co-morbidity/risk factor
169 Figure 54: Percentage of CHF patients across the US, Japan, and five major EU markets who are over the age of 65, diagnosed with hypertension, or diagnosed with CAD
172 Figure 55: Percentage of CHF patients diagnosed with HFrEF and HFpEF across the US, Japan, and five major EU markets, by country
175 Figure 56: Percentage of patients with HFrEF in each NYHA class, by country
176 Figure 57: Percentage of patients with HFpEF in each NYHA class, by country
182 Figure 58: Percentage of HFrEF patients receiving each treatment type, by NYHA class
184 Figure 59: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFrEF, by NYHA class and country
185 Figure 60: Percentage of regimens containing beta blockers for the first-line treatment of HFrEF, by NYHA class and country
186 Figure 61: Percentage of regimens containing ARBs for the first-line treatment of HFrEF, by NYHA class and country
187 Figure 62: Percentage of regimens containing ARBs for the treatment of HFrEF, by NYHA class and line of treatment
188 Figure 63: Percentage of regimens containing diuretics for the first-line treatment of HFrEF, by country and NYHA class
189 Figure 64: Percentage of regimens containing MRAs for the first-line treatment of HFrEF, by country and NYHA class
190 Figure 65: Percentage of regimens containing SGLT-2 inhibitors for the first-line treatment of HFrEF, by country and NYHA class
191 Figure 66: Percentage of regimens containing the SGLT-2 inhibitors Jardiance and Farxiga for the first-line treatment of HFrEF, by NYHA class
192 Figure 67: Top three drug regimens for first-line treatment of class I HFrEF, by country
193 Figure 68: Top three drug regimens for second-line treatment of class I HFrEF, by country
194 Figure 69: Top three drug regimens for first-line treatment of class II–III HFrEF, by country
195 Figure 70: Top three drug regimens for second-line treatment of class II–III HFrEF, by country
196 Figure 71: Top three drug regimens for first-line treatment of class IV HFrEF, by country
197 Figure 72: Top three drug regimens for second-line treatment of class IV HFrEF, by country
200 Figure 73: Percentage of HFpEF patients receiving each treatment type, by NYHA class
201 Figure 74: Percentage of regimens containing ACE inhibitors for the first-line treatment of HFpEF, by NYHA class and country
202 Figure 75: Percentage of regimens containing ARBs for the first-line treatment of HFpEF, by NYHA class and country
203 Figure 76: Percentage of regimens containing beta blockers for the first-line treatment of HFpEF, by country and NYHA class
204 Figure 77: Percentage of regimens containing diuretics for the first-line treatment of HFpEF, by country and NYHA class
205 Figure 78: Percentage of regimens containing MRAs for the first-line treatment of HFpEF, by country and NYHA class
206 Figure 79: Top three drug regimens for first-line treatment of class I HFpEF, by country
207 Figure 80: Top three drug regimens for second-line treatment of class I HFpEF, by country
208 Figure 81: Top three drug regimens for first-line treatment of class II–III HFpEF, by country
209 Figure 82: Top three drug regimens for second-line treatment of class II–III HFpEF, by country
210 Figure 83: Top three drug regimens for first-line treatment of class IV HFpEF, by country
211 Figure 84: Top three drug regimens for second-line treatment of class IV HFpEF, by country
213 Figure 85: Compliance rates of chronic heart failure patients in the US, Japan, and five major EU markets, by country and ejection fraction
228 Figure 86: Trends in diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
255 Figure 87: Corlanor for chronic heart failure – SWOT analysis
256 Figure 88: Datamonitor Healthcare’s drug assessment summary of Corlanor for chronic heart failure
257 Figure 89: Datamonitor Healthcare’s drug assessment summary of Corlanor for chronic heart failure
259 Figure 90: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
266 Figure 91: Entresto for chronic heart failure – SWOT analysis
267 Figure 92: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
268 Figure 93: Datamonitor Healthcare’s drug assessment summary of Entresto for chronic heart failure
273 Figure 94: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
280 Figure 95: European Society of Cardiology Heart Failure guidelines
281 Figure 96: American College of Cardiology/American Heart Association/Heart Failure Society of America guidelines
345 Figure 97: Price sources and calculations for the US and EU, by country
354 Figure 98: C-Cure for chronic heart failure – SWOT analysis
355 Figure 99: Datamonitor Healthcare’s drug assessment summary of C-Cure for chronic heart failure
356 Figure 100: Datamonitor Healthcare’s drug assessment summary of C-Cure for chronic heart failure
358 Figure 101: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
363 Figure 102: Farxiga for chronic heart failure – SWOT analysis
364 Figure 103: Datamonitor Healthcare’s drug assessment summary of Farxiga for chronic heart failure
365 Figure 104: Datamonitor Healthcare’s drug assessment summary of Farxiga for chronic heart failure
367 Figure 105: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
373 Figure 106: Jardiance for chronic heart failure – SWOT analysis
374 Figure 107: Datamonitor Healthcare’s drug assessment summary of Jardiance for chronic heart failure
375 Figure 108: Datamonitor Healthcare’s drug assessment summary of Jardiance for chronic heart failure
377 Figure 109: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
383 Figure 110: MPC-150-IM for chronic heart failure – SWOT analysis
384 Figure 111: Datamonitor Healthcare’s drug assessment summary of MPC-150-IM for chronic heart failure
385 Figure 112: Datamonitor Healthcare’s drug assessment summary of MPC-150-IM for chronic heart failure
387 Figure 113: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
394 Figure 114: Xarelto for chronic heart failure – SWOT analysis
395 Figure 115: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
396 Figure 116: Datamonitor Healthcare’s drug assessment summary of Xarelto for chronic heart failure
398 Figure 117: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
404 Figure 118: Omecamtiv mecarbil for chronic heart failure – SWOT analysis
405 Figure 119: Datamonitor Healthcare’s drug assessment summary of omecamtiv mecarbil for chronic heart failure
406 Figure 120: Datamonitor Healthcare’s drug assessment summary of omecamtiv mecarbil for chronic heart failure
408 Figure 121: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
414 Figure 122: Vericiguat for chronic heart failure – SWOT analysis
415 Figure 123: Datamonitor Healthcare’s drug assessment summary of vericiguat for chronic heart failure
416 Figure 124: Datamonitor Healthcare’s drug assessment summary of vericiguat for chronic heart failure
418 Figure 125: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
25 Table 1: Chronic heart failure drug sales across the US, Japan, and five major EU markets, by country ($m), 2017–26
27 Table 2: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
30 Table 3: SGLT-2 inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
32 Table 4: Generic ACE inhibitor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
34 Table 5: Generic ARB sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
35 Table 6: Generic ACE inhibitor patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
36 Table 7: Generic ARB patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
37 Table 8: Stem cell therapy sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
39 Table 9: Stem cell therapy patient numbers for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017–26
41 Table 10: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
43 Table 11: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
45 Table 12: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
49 Table 13: Chronic heart failure drug sales across the US and five major EU markets, by country ($m), 2017–26
52 Table 14: Summary of drug classes and molecules included in Datamonitor Healthcare’s chronic heart failure patient-based forecast
57 Table 15: Exchange rates used for calculating prices
58 Table 16: Cardiologists surveyed for the chronic heart failure primary research study, 2017
64 Table 17: C-Cure drug profile
64 Table 18: C-Cure proposed Phase III trial design in chronic heart failure
65 Table 19: C-Cure completed late-phase data in chronic heart failure
71 Table 20: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
73 Table 21: Corlanor drug profile
75 Table 22: Corlanor pivotal Phase III trial data in chronic heart failure
77 Table 23: Corlanor Phase II trial data in chronic heart failure
83 Table 24: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
85 Table 25: Entresto drug profile
87 Table 26: Entresto Phase III data in chronic heart failure
88 Table 27: Ongoing pivotal trials for Entresto in chronic heart failure
97 Table 28: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
101 Table 29: Farxiga drug profile
101 Table 30: Farxiga Phase III trials in chronic heart failure
107 Table 31: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
110 Table 32: Jardiance drug profile
111 Table 33: Jardiance Phase III trials in chronic heart failure
117 Table 34: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
120 Table 35: MPC-150-IM drug profile
121 Table 36: MPC-150-IM late-phase trials in chronic heart failure
127 Table 37: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
131 Table 38: Xarelto drug profile
132 Table 39: Xarelto Phase III data in chronic heart failure
138 Table 40: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
141 Table 41: Omecamtiv mecarbil drug profile
142 Table 42: Omecamtiv mecarbil Phase III study in chronic heart failure
142 Table 43: Omecamtiv mecarbil Phase II data in chronic heart failure
148 Table 44: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
151 Table 45: Vericiguat drug profile
152 Table 46: Vericiguat Phase III trials in chronic heart failure
152 Table 47: Vericiguat Phase II data in chronic heart failure
158 Table 48: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
162 Table 49: Cardiologists surveyed for the chronic heart failure primary research study, 2017
165 Table 50: Common laboratory test abnormalities in chronic heart failure
171 Table 51: Definitions of HFrEF and HFpEF
173 Table 52: New York Heart Association functional classification based on severity of symptoms and physical activity
174 Table 53: Comparison of ACCF/AHA stages of HF with NYHA functional classification
179 Table 54: Treatments available for chronic heart failure across the US, Japan, and five major EU markets
215 Table 55: NYHA functional classes I–IV, classification summary
218 Table 56: Sources used for the epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country
220 Table 57: Sources used for the previous epidemiological analysis of CHF in the US, Japan, and five major EU markets, by country (published 9 October 2017)
225 Table 58: Diagnosed prevalent cases of CHF in the US, Japan, and five major EU markets, by country, 2018–38
236 Table 59: Key marketed drugs for chronic heart failure
238 Table 60: Angiotensin-converting enzyme inhibitors class overview
241 Table 61: Angiotensin receptor blocker class overview
243 Table 62: Beta blocker class overview
246 Table 63: Aldosterone antagonists class overview
248 Table 64: Other drug class overview
250 Table 65: Corlanor drug profile
252 Table 66: Corlanor pivotal Phase III trial data in chronic heart failure
254 Table 67: Corlanor Phase II trial data in chronic heart failure
260 Table 68: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
262 Table 69: Entresto drug profile
264 Table 70: Entresto Phase III data in chronic heart failure
265 Table 71: Ongoing pivotal trials for Entresto in chronic heart failure
274 Table 72: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
279 Table 73: Regulatory labels for Entresto in the US, Japan, and five major EU markets
285 Table 74: Reimbursement restrictions for Entresto across the US and five surveyed EU markets
286 Table 75: Primary and secondary care prescribing of Entresto in the five major EU markets
288 Table 76: Use of efficiency audits for Entresto in the five major EU markets
291 Table 77: Payer concerns surrounding the Phase III PARADIGM-HF patient population
293 Table 78: Payer views on the primary and secondary endpoints used in the Phase III PARADIGM-HF trial
294 Table 79: Impact of reduction in CHF hospitalization for Entresto across the US and five major EU markets
297 Table 80: Impact of Entresto’s HRQoL benefits across the five major EU markets
303 Table 81: Benefits of Jardiance versus Entresto
305 Table 82: Pricing of Entresto in the US and five major EU markets, by country
307 Table 83: Formulary placement of Entresto in selected commercial formularies
309 Table 84: Formulary placement of Entresto in selected Medicare Part D formularies
311 Table 85: Prior authorization criteria for Entresto in eight major health plans
315 Table 86: CADTH assessment of Entresto
319 Table 87: Transparency Committee’s ASMR ratings and pricing implications
319 Table 88: Transparency Committee’s SMR ratings and pricing implications
320 Table 89: Transparency Committee’s assessment of Entresto
327 Table 90: G-BA assessment of Entresto
331 Table 91: Reimbursement conditions for Entresto in Italy
334 Table 92: National and regional reimbursement decisions in Spain
337 Table 93: NICE assessment of Entresto
341 Table 94: SMC assessment of Entresto
346 Table 95: Exchange rates used for calculating branded drug prices
349 Table 96: Profiled pipeline products in development for chronic heart failure
352 Table 97: C-Cure drug profile
352 Table 98: C-Cure proposed Phase III trial design in chronic heart failure
353 Table 99: C-Cure completed late-phase data in chronic heart failure
359 Table 100: C-Cure sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
362 Table 101: Farxiga drug profile
362 Table 102: Farxiga Phase III trials in chronic heart failure
368 Table 103: Farxiga sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
371 Table 104: Jardiance drug profile
372 Table 105: Jardiance Phase III trials in chronic heart failure
378 Table 106: Jardiance sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
381 Table 107: MPC-150-IM drug profile
382 Table 108: MPC-150-IM late-phase trials in chronic heart failure
388 Table 109: MPC-150-IM sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
392 Table 110: Xarelto drug profile
393 Table 111: Xarelto Phase III data in chronic heart failure
399 Table 112: Xarelto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
402 Table 113: Omecamtiv mecarbil drug profile
403 Table 114: Omecamtiv mecarbil Phase III study in chronic heart failure
403 Table 115: Omecamtiv mecarbil Phase II data in chronic heart failure
409 Table 116: Omecamtiv mecarbil sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26
412 Table 117: Vericiguat drug profile
413 Table 118: Vericiguat Phase III trials in chronic heart failure
413 Table 119: Vericiguat Phase II data in chronic heart failure
419 Table 120: Vericiguat sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017–26